



CODEN [USA]: IAJPBB

ISSN: 2349-7750

INDO AMERICAN JOURNAL OF  
**PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.3694125>Available online at: <http://www.iajps.com>

Research Article

**ATRIAL FIBRILLATION IN COPD**<sup>1</sup>Dr. SYED MOHSIN ALI, <sup>3</sup>Dr. HAFSA NAZIR MALIK, <sup>2</sup>Dr. KANZA REHMAN<sup>1</sup>School of Medicine and Nursing, Dezhou University, Shandong, China<sup>2</sup>Sheikh Zayed Hospital, Rahim Yar Khan, Pakistan<sup>3</sup>Bahawal Victoria Hospital, Bahawalpur, Pakistan**Article Received:** December 2019    **Accepted:** January 2020    **Published:** February 2020**Abstract:**

**Objective;** To assess the frequency of atrial fibrillation in cases presenting with COPD. **Material and methods;** This cross sectional study was conducted during January to July 2019. There were 400 patients included. The cases were labelled as COPD according to GOLD 2015 guidelines. Atrial fibrillation was labelled as yes on the basis of absent p wave and irregular heart rate. **Results;** In the present study, there were total 400 cases of COPD, out of which 328 (82%) were males and 72 (8%) were females. The mean age at presentation was 57.11±9.82 years. There were 232 (58%) cases that had COPD for more than 3 years and 272 (68%) of cases had class IV of COPD. Atrial fibrillation was seen in 72 (18%) of the cases. Atrial fibrillation was seen in 52 (22.41%) out of 232 cases that had COPD more than 3 years with  $p= 0.02$ . There was no significant difference in terms of severity of COPD where it was seen in 20 (15.62%) cases with class III and 52 (19.12%) cases of class IV out of their respective groups with  $p= 0.43$ . **Conclusion;** Atrial fibrillation is not uncommon complication of COPD and it is significantly associated with duration of COPD more than 5 years.

**Key words;** COPD, Atrial fibrillation,**Corresponding author:****Dr Syed Mohsin Ali,**

School of Medicine and Nursing,

Dezhou University, Shandong, China

[dr\\_syedmohsinali@yahoo.com](mailto:dr_syedmohsinali@yahoo.com)

QR code



Please cite this article in press Syed Mohsin Ali Rani et al, *Atrial Fibrillation In COPD.*, Indo Am. J. P. Sci, 2020; 07(02).

**INTRODUCTION:**

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases<sup>1</sup>

COPD is a chronic debilitating disease that can increase the morbidity and mortality worldwide. Its number is highest in the developing countries. Various risk factors can predispose to this condition. Tobacco exposure is the most common one, followed by biomass fuel burning and indoor and outdoor pollution. The rate of smoking as well as pollution is rising and so are the cases of COPD, which is thought to be the 3<sup>rd</sup> leading causes of death in next 20 years.<sup>2-3</sup>

The risk factors for COPD are also similar to that of ischemic heart disease and predispose to the cardiac disorders. Moreover, the dilated heart due to cor pulmonale also serves as a source to predispose for different arrhythmias like Atrial fibrillation.<sup>3</sup> Higher age, smoking habits, co morbid hypertension, diabetes mellitus are major risk factors for COPD as well as different arrhythmias.<sup>4-5</sup>

Quality of life is impaired in presence of comorbid conditions even in early stages of COPD.<sup>6</sup> Comorbid conditions may coexist with COPD as independent entity or it may have same risk factors/pathology as that of COPD. Such patients require multiple therapeutic interventional approach<sup>7-9</sup>

**OBJECTIVE;**

To assess the frequency of atrial fibrillation in cases presenting with COPD. **MATERIAL AND METHODS.**

This cross sectional study was conducted during January to July 2019. The detailed demographic data was collected and cases were selected via non probability consecutive sampling via following criteria:

**Inclusion criteria;**

Either genders with age range of 40 years or more with COPD, diagnosed on the basis of GOLD guidelines 2015 of severity III and IV presenting to in patient departments were included.

**Exclusion criteria;**

1. The cases of end stage liver or cardiac disease
2. The cases with electrolyte imbalance

The detailed socio demographic and clinical data was collected. Atrial fibrillation was labelled as yes when the p wave was absent and the R-R interval was variable. The data was entered and analysed using SPSS 21 version. Post stratification chi square test was applied taking p value < 0.05 as significant.

**RESULTS:**

In the present study, there were total 400 cases of COPD, out of which 328 (82%) were males and 72 (8%) were females. The mean age at presentation was 57.11±9.82 years. There were 232 (58%) cases that had COPD for more than 3 years and 272 (68%) of cases had class IV of COPD. Atrial fibrillation was seen in 72 (18%) of the cases. Atrial fibrillation was seen in 52 (22.41%) out of 232 cases that had COPD more than 3 years with p= 0.02. There was no significant difference in terms of severity of COPD where it was seen in 20 (15.62%) cases with class III and 52 (19.12%) cases of class IV out of their respective groups with p= 0.43 as shown in the table 1.

**TABLE 1**  
**ATRIAL FIBRILLATION VS STUDY VARIABLES**  
n= 400

Duration of COPD	Atrial Fibrillation		Total	P Value
	Yes	No		
< 3 years	20 (11.90%)	148 (88.10%)	168 (42%)	0.02
> 3 years	52 (22.41%)	180 (77.59%)	232 (58%)	
Class of COPD	Atrial Fibrillation		Total	P Value
	Yes	No		
III	20 (15.62%)	148 (84.38%)	128 (32%)	0.43
IV	52 (19.12%)	220 (80.88%)	272 (68%)	

**DISCUSSION:**

COPD is among the top 5 leading causes of death globally and it is considered to be the 3<sup>rd</sup> leading cause of death by 2030. Multiple co morbid conditions can accelerate the severity and clinical spectrum of COPD and Atrial fibrillation in one of the salient ones.

In the present study, in cases of COPD, the atrial fibrillation was observed in 72 (18%) of the cases. This was also similar to the data in the previous studies where its prevalence has been seen in the range of 11-15% of the cases of COPD.<sup>10-11</sup>

The rate of atrial fibrillation was significantly high in cases that had duration of COPD for more than 5 years where it was seen in 52 (22.41%) out of 58 cases that had COPD more than 5 years with  $p=0.02$ . This was also reinforced by the other studies. According to study done by Huang B et al and Li J et al, both revealed significantly high number of this complication; however the cut off values in their study were slightly different.<sup>12-13</sup> The latter study has shown as high as 30% of the cases to suffer from this. The reason of this high number can be explained by the fact that the chronic is the disease and higher are the chances to not only develop cor pulmonale due to stress over the right side of the heart, but also hypoxia and the increased risk of cardiovascular disease due to sharing of the common risk factors, that pose such cases to develop various arrhythmias including atrial fibrillation.

There was no significant difference in terms of severity of COPD where it was seen in 20 (15.62%) cases with class III and 52 (19.12%) cases of class IV out of their respective groups with  $p=0.43$ . In the past not much work is done in such context to look for this aspect. However, the studies have shown that the severe disease has high chances to develop this.<sup>14-15</sup> The lack of significant difference in such cases may be due to the inclusion criteria as we included the cases of in patient that had admission with an acute exacerbation, which might show the more severe form than their baseline. So, the base line disease has not posed a great risk to develop this complication.

**CONCLUSION:**

Atrial fibrillation is not uncommon complication of COPD and it is significantly associated with duration of COPD more than 5 years.

**REFERENCES:**

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Revised 2014.

Available from: <http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html>. Accessed March 20, 2017.

2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med.* 2007;176(6):532–555.
3. World Health Organization. Chronic obstructive pulmonary disease (COPD). 2011. Available from: <http://www.who.int/respiratory/copd> <http://www.who.int/respiratory/copd>. Accessed March 20, 2017.
4. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. *Proc Am Thorac Soc.* 2008;5(4):549–555.
5. Tsiligianni IG, Kosmas E, Van der Molen T, Tzanakis N. Managing comorbidity in COPD: a difficult task. *Curr Drug Targets.* 2013;14(2): 158–176.
6. Koskela J, Kilpeläinen M, Kupiainen H, et al. Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. *BMC Pulm Med.* 2014;14(1):102-05.
7. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M. Defining comorbidity: implications for understanding health and health services. *Ann Fam Med.* 2009;7(4):357–36.
8. Bower P, Macdonald W, Harkness E, et al. Multiborbidity, service organization and clinical decision making in primary care: a qualitative study. *Fam Pract.* 2011;28(5):579–587.
9. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2012;186(2):155–161.
10. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur Heart J.* 2010;31(19):2369-429. Erratum in: *Eur Heart J.* 2011;32(9):1172.
11. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. *Chest.* 2005;128(4):2068-75.

12. Li J, Agarwal SK, Alonso A, Blecker S, Chamberlain AM, London SJ, et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation*. 2014;129(9):971-80.
13. Huang B, Yang Y. Radiofrequency catheter ablation of atrial fibrillation in patients with chronic obstructive pulmonary disease: opportunity and challenge: response to Dr Kumar's comment. *J Am Med Dir Assoc*. 2015;16(1):83-4.
14. Caglar IM, Dasli T, Turhan Caglar FN, Teber MK, Ugurlucan M, Ozmen G. Evaluation of atrial conduction features with tissue Doppler imaging in patients with chronic obstructive pulmonary disease. *Clin Res Cardiol*. 2012;101(8):599-606.
15. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. *Thorax*. 2012;67(11):970-6.